Notably, experimental depletion of monocyte‐derived macrophages using clodronate liposomes, or direct inhibition of Osteopontin, has been shown to reduce tumour recurrence and improve anti‐tumour immunity in preclinical models, highlighting SPP1 as a potential therapeutic target to prolong relapse‐free survival [50]. This evidence concerns the gene SPP1 and neoplasm.